Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

Cohort study (n=763) found that those with a high Immunoscore had a significantly greater survival and time to disease recurrence than those with a lower score. Authors suggest patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.


Journal of Clinical Oncology